TYRP1 and uveal melanoma: In a phase I clinical trial, the vesicular stomatitis virus (VSV) expressing interferon beta (IFN-β) and tyrosinase-related protein 1 (TYRP1) demonstrated safety and induced dose-dependent immunogenicity and T-cell responses in uveal melanoma [6].